These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 7662446)

  • 1. Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.
    Feher MD; Foxton J; Banks D; Lant AF; Wray R
    Br Heart J; 1995 Jul; 74(1):14-7. PubMed ID: 7662446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of primary hypercholesterolaemia with simvastatin. New Zealand multicentre evaluation.
    Lintott CJ; Scott RS; Sharpe DN; Nye ER; Charleson H; French JK; White HD; Reuben S; Maling TJ; Lewis GR
    Med J Aust; 1991 Oct; 155(7):433-6. PubMed ID: 1921811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia.
    Ellen RL; McPherson R
    Am J Cardiol; 1998 Feb; 81(4A):60B-65B. PubMed ID: 9526816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
    Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Didangelos TP; Carina MV; Kranitsas DF; Kontopoulos AG
    Am J Cardiol; 1997 Sep; 80(5):608-13. PubMed ID: 9294990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
    Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential associations of statin and fibrate treatment with carotid arterial remodeling.
    Chironi G; Simon A; Gariepy J; Balice M; Del-Pino M; Levenson J
    Am J Hypertens; 2005 Nov; 18(11):1476-81. PubMed ID: 16280285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
    Pedersen TR; Tobert JA
    Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations.
    Oldemeyer JB; Lund RJ; Koch M; Meares AJ; Dunlay R
    Cardiology; 2000; 94(2):127-8. PubMed ID: 11173785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials.
    Farnier M; Marcereuil D; De Niet S; Ducobu J; Steinmetz A; Retterstøl K; Bryniarski L; Császár A; Vanderbist F
    Clin Drug Investig; 2012 Apr; 32(4):281-91. PubMed ID: 22350498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
    Farnier M; Averna M; Missault L; Vaverkova H; Viigimaa M; Massaad R; Vandormael K; Johnson-Levonas AO; Brudi P
    Int J Clin Pract; 2009 Apr; 63(4):547-59. PubMed ID: 19222610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the effects of simvastatin and pravastatin monotherapy on muscle histology and permeability in hypercholesterolaemic patients.
    Contermans J; Smit JW; Bär PR; Erkelens DW
    Br J Clin Pharmacol; 1995 Feb; 39(2):135-41. PubMed ID: 7742151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects and side effects of a 1-year treatment of primary hypercholesterolemia with simvastatin].
    Brocard JJ; Keller U; Oberhänsli A; Riesen WF
    Schweiz Med Wochenschr; 1991 Jun; 121(26):977-83. PubMed ID: 1862314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
    Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A
    Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
    Branchi A; Rovellini A; Sommariva D; Gugliandolo AG; Fasoli A
    Thromb Haemost; 1993 Aug; 70(2):241-3. PubMed ID: 8236126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults.
    Carlsson CM; Papcke-Benson K; Carnes M; McBride PE; Stein JH
    Drugs Aging; 2002; 19(10):793-805. PubMed ID: 12390056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effectiveness and tolerability of simvastatin in patients with moderate-to-severe hypercholesterolemia. Results of a 12-month study].
    Ghizzoni G; Rusconi C; Faggiano P; Sabatini T; Oneglia C; Gardini A
    Minerva Cardioangiol; 1993 Mar; 41(3):105-9. PubMed ID: 8510811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?
    Glueck CJ; Rawal B; Khan NA; Yeramaneni S; Goldenberg N; Wang P
    Metabolism; 2009 Feb; 58(2):233-8. PubMed ID: 19154957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.
    Alford JC; Saseen JJ; Allen RR; Nair KV
    Pharmacotherapy; 2012 Jul; 32(7):623-30. PubMed ID: 22570173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The patient at risk: who should we be treating?
    Shviro I; Leitersdorf E
    Br J Clin Pract Suppl; 1996 Jan; 77A():24-7. PubMed ID: 8729587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.